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Secondary Prevention of Esophageal Squamous Cell
Carcinoma in Areas Where Smoking, Alcohol, and
Betel Quid Chewing are Prevalent
Chen-Shuan Chung,1,2† Yi-Chia Lee,1† Cheng-Ping Wang,3,4 Jenq-Yuh Ko,4 Wen-Lun Wang,1,5
Ming-Shiang Wu,1* Hsiu-Po Wang1*
Esophageal cancer is ranked as the sixth most common cause of cancer death worldwide and has a sub-
stantial effect on public health. In contrast to adenocarcinoma arising from Barrett’s esophagus in Western
countries, the major disease phenotype in the Asia–Pacific region is esophageal squamous cell carcinoma
which is attributed to the prevalence of smoking, alcohol, and betel quid chewing. Despite a multidisciplin-
ary approach to treating esophageal cancer, the outcome remains poor. Moreover, field cancerization re-
veals that esophageal squamous cell carcinoma is closely linked with the development of head and neck
cancers that further sub-optimize the treatment of patients. Therefore, preventive strategies are of para-
mount importance to improve the prognosis of this dismal disease. Since obstacles exist for primary pre-
vention via risk factor elimination, the current rationale for esophageal cancer prevention is to identify
high-risk groups at earlier stages of the disease, and encourage them to get a confirmatory diagnosis,
prompt treatment, and intensive surveillance for secondary prevention. Novel biomarkers for identifying
specific at-risk populations are under extensive investigation. Advances in image-enhanced endoscopy do
not just substantially improve our ability to identify small precancerous or cancerous foci, but can also ac-
curately predict their invasiveness. Research input from the basic sciences should be translated into pre-
ventive measures in order to decrease the disease burden of esophageal cancer.
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Disease Burden of Esophageal 
Squamous Cell Carcinoma
In parallel with the increase of metabolic dis-
orders, gastroesophageal reflux disease and its
complications have become one of the most
prevalent diseases globally.1,2 However, in con-
trast with esophageal adenocarcinoma arising
from Barrett’s esophagus in Western countries,
the major disease phenotype in the Asia–Pacific
region is esophageal squamous cell carcinoma
(ESCC).3 In Taiwan, the standardized death rate
for esophageal cancer increased from 3.6 (5.9 in
males) to 5.0 (9.3 in males) per 100,000 popula-
tion in the period 1992 to 2008, and this disease
currently ranks as the ninth leading cause of can-
cer deaths.4 The most susceptible age for esoph-
ageal cancer has decreased. In 2008, the median
age of death was 58 years for males, which is a 
7-year decrease compared with that of 1998.4 If
we combine oral cancer, hypopharyngeal cancer,
and esophageal cancer into a single disease cate-
gory, it may be the second most common cancer
in men in Taiwan and is increasing at a rapid rate.
Collectively, the distinct epidemiologic charac-
teristics of esophageal cancer to Western countries
suggest strategies to prevent esophageal cancer
are crucial and must be tailored to the needs of
this region.
Primary Prevention of 
Esophageal Cancer
Risk factors for ESCC include carcinogen expo-
sure, hot tea drinking, chronic mucosal irritation,
a family history of malignancy, and pre-existing
tumors of the aero-digestive tract.3 Also, lower
body mass index, lower educational level, and
poorer socioeconomic status were found in pa-
tients with esophageal cancer.5 Among protective
factors are citrus fruits and yellow and green veg-
etables, which contain vitamin C and β-carotene.6
In a Japanese study, an increase in consumption
of total vegetables and fruit by 100 grams per day
was associated with an 11% decrease in the risk
of esophageal cancer.6 Coffee consumption and
some medications, such as angiotensin-converting
enzyme inhibitors, aspirin, and non-steroidal
anti-inflammatory drugs, might protect against
esophageal cancer.7,8
Abstinence from smoking, alcohol ingestion,
and betel quid chewing is mandated for cancer
prevention. Many case-control studies have con-
firmed their carcinogenic effects (Table 1).9–29
Smoking [odds ratio (OR) = 1.6–16.9; summa-
rized OR = 2.6, 95% confidence interval (CI) =
2.4–2.9], alcohol consumption [OR = 1.1–17.6;
summarized OR = 2.7, 95% CI = 2.5–2.9], and
betel quid chewing (OR = 1.6–9.4; summarized
OR = 7.2, 95% CI = 4.5–11.3) increase the risk of
esophageal cancer in a dose-dependent relation-
ship as well as synergistic effects.9–30 For instance,
the concomitant use of alcohol and tobacco leads
to a higher risk with an OR of 8 and further adding
betel quid chewing can augment the OR to 195.6
(95% CI = 64.0–864.2).19,25
Focus on Betel Quid Chewing
Betel quid chewing is a common behavior in
South and Southeast Asia.3 In addition to its car-
cinogenic effect, betel quid chewing is associated
with obesity, hypertriglyceridemia, hyperglycemia,
metabolic syndrome, cardiovascular disease, he-
patic dysfunction, cirrhosis of the liver and liver
cancer.31–33 Exposure of parents to betel nut may
transgenerationally increase the risk of metabolic
syndrome in their offspring.34
Biologically, the constituents of betel nuts
may inhibit expression of the p53 tumor sup-
pressor, impair DNA repair, and activate matrix
metalloproteinases-2, -8, and -9, which may ac-
celerate tumor migration.35,36 Adding slaked lime
can decrease the astringent taste of the raw betel
fruit and chewing with Piper betel Linn can 
increase the refreshing taste, but both of these
additives increase the risk of esophageal cancer.21
Swallowing betel quid juice also increases 
the risk of esophageal cancer (OR = 3.3; 95%
CI = 1.3–9.3).25
C.S. Chung, et al
410 J Formos Med Assoc | 2010 • Vol 109 • No 6
Host Susceptibility to Esophageal Cancer
Males are more susceptible to this disease and
prone to be at a more advanced stage when symp-
tomatic.27 Familial aggregation of this cancer is a
well known phenomenon.24 Genetic polymor-
phisms regulating folate metabolism are related
to an increase of host susceptibility. Subjects with
the methylenetetrahydrofolate reductase 677 TT
genotype were found to be at higher risk (OR =
2.63, 95% CI=1.75–3.94).37 Also, the interleukin-6
(–174G > C) promoter gene polymorphism is as-
sociated with a higher risk (OR = 2.26, 95% CI =
1.37–3.73).38
Alcohol is metabolized to acetaldehyde by al-
cohol dehydrogenase (ADH) and the aldehyde
Table 1. Association between alcohol consumption, smoking, betel quid chewing and the risk of esophageal
squamous cell carcinoma
Year/ Case/ Alcohol*
Smoking*
Betel quid 
Reference
location control (n) consumption chewing*
1981/US 120/250 6.4 (2.5–16.4) 1.3 (0.8–2.4) – Pottern et al [9]
1988/US 275/275 15.5 (5.9–41.1)a 11.5 (4.5–29.8)b – Yu et al [10]
1990/Uruguay 261/522 5.3 (2.7–10.2)c 4.6 (1.9–11.1)d – De Stefani et al [11]
1990/US 178/174 3.1 (1.7–5.7)e 2.1 (1.1–3.9)f – Graham et al [12]
1990/Italy 288/1272 6.0 (3.7–10.0)g 3.8 (2.2–6.6) – Franceschi et al [13]
1991/India 267/895 2.3 (1.5–3.6) 4.8 (2.3–9.8)h – Sankaranarayana et al [14]
1992/Hong Kong 400/1598 11.5 (5.7–19.7)i 5.8 (2.8–12.0)j – Cheng et al [15]
1994/China 902/1552 1.4 1.9 – Gao et al [16]
1994/Argentina 131/262 2.9 (1.4–6.1) 2.9 (1.5–5.6) – Castelletto et al [17]
1995/US 106/724 9.5 (4.0–22.3)k 16.9 (4.1–69.1)l – Thomas et al [18]
1999/Argentina, 830/1779 1.8 (1.2–2.6) 2 (1.4–2.8) – Castellsague et al [19]
Brazil, Paraguay, 
and Uruguay
2000/Sweden 167/820 1.1 (0.6–2.1) 9.3 (5.1–17.0)m – Lagergren et al [20]
2001/Taiwan 104/277 9.8 (4.2–22.6)n 3.7 (1.6–8.7)o 9.4 (1.8–48.3)p Wu et al [21]
2003/Italy 395/1066 – 5.1 (3.3–7.7)m – Gallus et al [22]
2005/Taiwan 513/818 7.6 (5.2–11.1)q 4.2 (2.7–6.3)m 2.3 (1.4–3.7)r Lee et al [23]
2005/Italy and 805/3461 3.5 (1.1–10.8)s 8.8 (2.8–28.0)m – Garavello et al [24]
Switzerland
2006/Taiwan 165/255 17.6 (9.3–35.2) 5.4 (2.4–12.9) 1.7 (0.8–3.1) Wu et al [25]
2007/Romania, 192/1114 2.86 (1.1–7.7) 7.4 (4.0–13.8)m – Hashibe et al [26]
Russia, Czech, 
and Poland
2007/China 355/408 Male: 2.2 (1.5–3.2)/ Male: 2 (1.3–2.9) – Wang et al [27]
Female: 0.8 (0.2–3.1)
2008/Iran 300/571 – 1.63 (1.0–2.8)m – Nasrollahzadeh et al [28]
2008/Australia 303/1580 1.05 (1.04–1.07) – – Pandeya et al [29]
*Data presented as odds ratios (95% confidence interval). The baseline comparators are: aalcohol < 120 g per day; bsmoking < 3 packs per
day; calcohol < 250 g per day; dsmoking < 25 cigarettes per day; ealcohol < 49 drinks per month; fsmoking < 48 pack-years; galcohol < 60
drinks per week; hsmoking < 21 cigarettes per day; ialcohol < 1000 g per week; jsmoking < 40 g per day; kalcohol < 21 drinks per week; lsmok-
ing < 80 pack-years; mnever smokers; nalcohol < 1220 g-years; osmoking < 30 pack years; pbetel quid < 495 betel years; qnever drinkers; rnever
chewers; salcohol < 49 drinks per week.
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dehydrogenase (ALDH) converts acetaldehyde to
acetate. Genetic polymorphisms encoding these
two enzymes determine different rates of alcohol
metabolism. A more rapid ethanol oxidation
rate, such as occurs in subjects with more active
ADH variants, and a slower acetaldehyde oxida-
tion, such as occurs in subjects with less active
ALDH variants, can lead to toxic accumulation of
acetaldehyde, an alcohol flushing response, and a
higher risk of esophageal cancer.39 Studies from
Yokoyama et al provided substantial evidence that
alleles of alcohol and acetaldehyde metabolism
genes modulate susceptibility to ESCC from al-
cohol consumption in Asian patients.40 A recent
European study also indicates that multiple ADH
genes are associated with the risk of ESCC.41
Esophageal Cancer in Patients with
Primary Head and Neck Cancer
Esophageal cancer can develop synchronously or
metachronously in patients with head and neck
cancers due to exposure to the same environ-
mental carcinogens, which is one of the most im-
portant risk indicators.42 Among head and neck
cancers, patients with hypopharyngeal cancer have
the highest risk for simultaneous esophageal
cancer with a prevalence rate of 10–25%.43 Thus
routine examination of the esophagus has re-
cently become a part of pre-treatment evaluation
for newly diagnosed hypopharyngeal cancer.43 In
addition, metachronous esophageal cancer can
develop in patients already treated for hypophar-
yngeal cancer with a relative risk of 12.4.42 Thus
endoscopic surveillance of the esophagus in pa-
tients with treated hypopharyngeal cancer also
becomes an important issue.44 Despite having a
lower incidence of a second primary esophageal
cancer than the incidence in hypopharyngeal can-
cer, patients with other head and neck cancers
originating from the oral cavity, oropharynx, and
larynx still have higher risks for esophageal can-
cer with relative risks of 1.5–8.6, 11.7, and 3.3
and absolute rates of 0.4–1.4%, 2.5%, and 0.5%
per year, respectively.42
Secondary Prevention for 
Esophageal Cancer
The population with exposure history to tobacco,
alcohol, and betel quid, and at risk for ESCC is
so large that performing endoscopic screening
for everyone may outnumber the capacity of en-
doscopists. Thus identification of high-risk sub-
jects for second-stage confirmatory endoscopy is
extremely important to optimize the utilization
of medical resources. To this end, biomarkers with
potential for accurately predicting cancer risk are
essential for the achievement of secondary pre-
vention (Table 2).45–61
Risk Stratification with Demographic
Risk Factors
It is simple and practical to use demographic risk
factors to triage individuals for endoscopy. Since
the incidence of esophageal cancer increases with
age, endoscopy has been proposed for patients over
40 years of age with alarming symptoms.62 Wei et al
proposed a predictive model for risk stratifica-
tion in China.48 In this multivariate model, more
household members, a family history of cancer,
higher systolic blood pressure, heating the home
without a chimney, and having lost more but not
all of their teeth were associated with a higher risk
of having esophageal dysplasia. However, the sen-
sitivity, specificity, and the area under the ROC
curve were only 57%, 54%, and 58%, respectively.
Health Risk Appraisal Models
As mentioned previously, alleles of alcohol and
acetaldehyde metabolism genes may modulate
the risk of ESCC from alcohol drinking. Varia-
tions in blood acetaldehyde levels and facial flush-
ing after alcohol are due to an inactive enzyme
system encoded by the ALDH2*1/*2 genotype
and have been associated with an increased risk
of esophageal cancer.63 Yokoyama et al, therefore,
proposed the health risk appraisal (HRA) models
C.S. Chung, et al
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to triage the Japanese population.58 Alcohol con-
sumption, smoking, green-yellow vegetables and
fruit intake, and the presence of facial flushing
after alcohol (HRA-F) or the ALDH2 genotype
(HRA-G) are included in the predictive models.
Receiver operating characteristic curve analysis of
the HRA-F model showed that when people in the
top 10% of risk scores were selected for endoscopy,
57.9% of cancer cases were expected to be included
(i.e. a sensitivity of 58%). The HRA-G model provi-
ded a slightly higher sensitivity of 65.4%. The area
under the curve was 0.84 and 0.86 for HRA-F and
HRA-G models, respectively. The same group vali-
dated these two HRA models in another Japanese
population receiving mass screening and con-
firmed their ability to predict esophageal and
pharyngeal cancers in the top 10% risk group.61
Serological Markers
Mean corpuscular volume was suggested as a
convenient candidate biomarker to identify male
drinkers with inactive ALDH2. A study from Japan
has evaluated whether macrocytosis (i.e. an in-
crease in mean corpuscular volume) is useful in the
prediction of esophageal cancer.45 With a cut-off
value of 106 fL, the sensitivity and specificity were
43% and 83%, respectively. Even after adjusting
for age, daily alcohol consumption, daily cigarette
smoking, body mass index, and ADH2/ALDH2
genotypes, the cancer risk related to macrocytosis
remained significant (OR = 2.75; 95% CI = 1.13–
6.67). Gastric fundic atrophy may result in the re-
duction of gastric acid, proliferation of bacteria,
and the production of carcinogens, such as ac-
etaldehyde and nitrosamines.64 Kamangar et al
found that a lower serum pepsinogen I/II ratio was
associated with an increased risk of esophageal
cancer.60 However, another study demonstrated
that a lower pepsinogen I/II ratio was only asso-
ciated with an elevated risk of gastric cancer but
not esophageal cancer.65 Serum angiopoietin-2 is
a regulator of tumor angiogenesis and Zhou et al
evaluated its ability to predict esophageal cancer.56
In patients with invasive esophageal cancer, the
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angiopoietin-2 levels were higher and the sensi-
tivity of this marker for diagnosis was 78.6%.
Nevertheless, the sensitivity was disappointingly
23.1% in the detection of superficial cancer.56
Molecular Markers Based on 
Biopsied Tissue
Genetic markers
Esophageal carcinogenesis is a multi-factorial and
multistage process from basal cell hyperplasia to
dysplasia, to carcinoma in situ, and eventually to
invasive carcinoma, which is accompanied by al-
terations of critical growth-regulatory genes in
each histologically detectable progression. Many
forms of genetic variations, such as single nucleo-
tide polymorphisms, chromosomal insertions,
deletions, duplications, and microsatellite insta-
bility have been reported to be associated with the
risks and prognosis of ESCC. Regarding the ge-
netic polymorphisms for ESCC, genes involved
in the metabolism pathway of carcinogens, DNA
repair, cell cycle and apoptosis have generally been
studied with great interest. These include families
of cytochrome p450, glutathione S-transferase,
microsomal epoxide hydrolase, ADH and ALDH
enzymes.66 Fagundes et al reported that p53 pro-
tein was expressed in a stepwise fashion from nor-
mal mucosa to dysplasia, and to carcinoma.49
Focusing on Lugol unstained areas, Kaneko et al
suggested that p53 mutations were detected
more frequently in dysplastic samples than non-
dysplastic ones.54 He et al identified loss of het-
erozygosity in cancerous and precancerous lesions,
and the frequency increased with the severity of
malignant transformation.57 Elucidation of these
gene–gene and gene–environment interactions
may provide novel insights into pathogenesis and
strategies to manage ESCC.
Epigenetic markers
Epigenetics are defined as chromatin and DNA
modifications without changes in the underlying
DNA coding sequence. Ishii et al found that 
the methylation of CpG islands increased from 
non-neoplastic epithelium to intraepithelial neo-
plasia, and to advanced cancer.55 Roth et al found
that the methylation of p16,MGMT,RARs2,CLDN3,
CRBP and MT1G tended to increase as histological
severity increased.51 Hibi et al found aberrant p16
promoter methylation in 82% of cancer tissues.67
Abbaszadegan et al showed that aberrant p16 pro-
moter methylation increased in subjects with a
family history of esophageal cancer.47 Adams et al
evaluated the feasibility of use of a panel of four
hypermethylated genes in the detection of subjects
with high-grade dysplasia.59 However, the sensitiv-
ity and specificity were only 50% and 65%, respec-
tively. Recently, Oka et al found that in mucosa of
patients with esophageal cancer, methylation lev-
els of five genes, including HOXA9, MT1M, NEFH,
RSPO4, and UCHL1, were significantly correlated
with smoking duration.68 These epigenetic changes
have great potential as novel targets for risk diag-
nosis and prevention of esophageal cancer.
Early Detection of Esophageal Cancer
With Endoscopy
Endoscopy is the gold standard for the diagnosis
of esophageal cancer and surveillance of patients
with precancerous lesions. Early stage esophageal
cancer tends to present with superficial spread-
ing, which is easily overlooked by standard white-
light illumination (Figure 1A). Recent advances
in image-enhanced endoscopy facilitate the accu-
rate detection of precancerous and superficial can-
cerous foci (Table 3).43,44,69–85 Esophageal cancer
confined to epithelium and lamina propria have
minimal risk of lymph node metastasis and can
be cured by endoscopic mucosal resection, sub-
mucosal dissection, and radiofrequency ablation,
whereas 8% of cancers with muscularis mucosa
invasion, and 17–49% of cancers with submucosal
invasion, have a risk of lymph node metastasis.86
Lugol’s chromoendoscopy
Since Lugol’s solution can react with glycogen 
in normal esophageal mucosa but not cancerous
lesions, it is widely used to identify superficial 
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lesions (Figure 1E). Previous studies have shown
that Lugol’s chromoendoscopy has higher sensi-
tivity and negative predictive values compared
with standard endoscopy, however, its specificity
and positive predictive value are lower.70,71,73,74
Shiozaki et al found that 89% of the esophageal
cancer disclosed after Lugol staining is at earlier
stages and may be cured by minimally invasive
treatment.69 Although Katada et al found that
only 17.3% of 434 biopsy specimens from Lugol
unstained areas indicated cancerous lesions,87
the presence of multiple unstained areas over the
esophagus was a strong predictor for esophageal
cancer (OR = 21.4; 95% CI = 10.63–43.08).77
A B
C D
E F
Figure. Endoscopic views of the esophagus. (A) White-light conventional endoscopy shows mildly hyperemic mucosa.
(B) Narrow-band imaging endoscopy reveals circumferential brownish discoloration. (C and D) Magnifying endoscopy
with a narrow-band imaging system shows intrapapillary capillary loop (IPCL) type VN. (E) Lugol’s chromoendoscopy
shows a circumferential Lugol-voiding area. (F) An endoscopic ultrasound discloses thickening of the esophageal wall
with involvement of the muscularis propria with T2 invasiveness.
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Narrow-band imaging and magnifying
endoscopy
Narrow-band imaging (NBI) can enhance visual-
ization of microvascular structures in superficial
mucosal layers,88 with the neoplastic lesion under
NBI appearing brownish (Figures 1A and 1B). The
size of the intrapapillary capillary loop in normal
esophageal mucosa is about 10 μm, which will
change during tumor angiogenesis. Magnifying
endoscopy with NBI can visualize these intrapap-
illary capillary loop patterns, enable differential
diagnosis between cancerous or noncancerous
lesions, and predict the invasiveness of cancer-
ous lesions (Figure 1C and 1D).78,88 The feasibil-
ity of NBI with a transnasal ultra-slim endoscope
has been confirmed for head and neck cancer pa-
tients with tumor-related airway compromise or
post-irradiation trismus.43,44,83 In comparison
with Lugol chromoendoscopy, NBI can especially
minimize the risk of obtaining false-positive re-
sults, especially in patients with multiple Lugol
unstained areas.83
Autofluorescence imaging
Autofluorescence imaging (AFI) systems produce
real-time pseudo-color from the computation of
detecting natural tissue fluorescence from endoge-
nous fluorophores.76,79 Mayinger et al used this
system to successfully detect patients with esoph-
ageal cancer.76 Uedo et al also found that AFI can
identify flat or isochromatic lesions, which could
easily be missed by conventional imaging.79 How-
ever, false-positive interpretations may happen
frequently in cases with benign ulceration or
non-specific inflammation.
Multiple Modality Approach in
Endoscopic Screening
The intention of image-enhanced endoscopy tech-
nologies is to increase the detection rate of small
precancerous and cancerous lesions. However,
since a perfect diagnostic tool is still lacking, sev-
eral efforts have evaluated the feasibility of mul-
tiple detection modalities in a single endoscopic
session, in which each modality may offer com-
plementary information that can minimize the
risk of obtaining false-negative results. For instance,
using NBI before spraying Lugol’s solution can
overcome the problem of the high false-positive
rate of Lugol chromoendoscopy.83 Advanced en-
doscopic technology has incorporated high-
definition white-light imaging, NBI, and AFI into
one system, namely the tri-modal system. A re-
cent study has confirmed its usefulness in screen-
ing for early cancerous lesions for patients with
Barrett’s esophagus.89 Further studies are needed
to evaluate the efficacy of this approach in the
screening of esophageal cancer.
The Cost-effectiveness Issue
Cost-effectiveness is a significant concern at pres-
ent. Lessons from Western countries showed that
screening and surveillance for Barrett’s esopha-
gus has an annual risk of 0.5–1.0% of becoming
esophageal adenocarcinoma.90,91 There was no
randomized trial evidence to support the robust-
ness of models and the variation in parameter 
selection between studies was large. In our popu-
lation, by contrast, the progression from precur-
sor lesions to invasive squamous cell carcinoma
is accelerated, simultaneous development of mul-
tiple cancers is common, and the cost of endo-
scopic screening is oppositely low. All of these
observations may support that screening and sur-
veillance are more likely to be cost-effective for
ESCC. However, our current evidence to support
this assumption is very limited and requires fur-
ther economic evaluation alongside cancer pre-
vention trials.
Conclusion
Although the avoidance of smoking, alcohol, and
betel quid chewing could reasonably decrease the
risk of esophageal cancer, the rigid control of these
substances remains unsuccessful. Accordingly, stud-
ies have focused on better methods to identify
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high-risk subjects and to improve the detect-
ability of small cancerous foci with endoscopy,
i.e. a two-staged approach. To enable first-stage
risk stratification, further validation of demo-
graphic and molecular markers is warranted. Im-
provement in modern endoscopic technology has
strongly enhanced our ability, in the second stage,
to confirm the diagnosis. Minimally invasive treat-
ments, such as local endoscopic resection, argon
plasma coagulation, and radiofrequency ablation,
are therefore possible. These techniques may pre-
serve swallowing, maintain quality of life, and
provide meaningful improvement with regards to
long-term prognosis.
Acknowledgment
The article was supported by research grants from
the National Science Council (98-2314-B-002-
089-MY3).
References
1. Shaheen NJ, Richter JE. Barrett’s oesophagus. Lancet
2009;373:850–61.
2. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk
factors on the natural course of gastro-oesophageal reflux
disease. Gut 2009;58:174–81.
3. Bolye P, Levin B. World cancer report 2008. Lyon:
International Agency for Research on Cancer.
4. National Department of Health, Taiwan, Republic of China.
Cancer Registry Annual Report 1972–2009.
5. Smith M, Zhou M, Whitlock G, et al. Esophageal cancer
and body mass index: results from a prospective study of
220,000 men in China and a meta-analysis of published
studies. Int J Cancer 2008;122:1604–10.
6. Yamaji T, Inoue M, Sasazuki S, et al. Fruit and vegetable
consumption and squamous cell carcinoma of the eso-
phagus in Japan: the JPHC study. Int J Cancer 2008;123:
1935–40.
7. Sjöberg T, García Rodríguez LA, Lindblad M. Angiotensin-
converting enzyme inhibitors and risk of esophageal 
and gastric cancer: a nested case-control study. Clin
Gastroenterol Hepatol 2007;5:1160–6.
8. Sadeghi S, Bain CJ, Pandeya N, et al. Aspirin, non-steroidal
anti-inflammatory drugs, and the risks of cancers of the
esophagus. Cancer Epidemiol Biomarkers Prev 2008;17:
1169–78.
9. Pottern LM, Morris LE, Blot WJ, et al. Esophageal cancer
among black men in Washington, D.C. 1. Alcohol, tobacco,
and other risk factors. J Natl Cancer Inst 1981;67:777–83.
10. Yu MC, Garabrant DH, Peters JM, et al. Tobacco, alcohol,
diet, occupation, and carcinoma of the esophagus. Cancer
Res 1988;48:3843–8.
11. De Stefani E, Muñoz N, Estève J, et al. Mate drinking, al-
cohol, tobacco, diet, and esophageal cancer in Uruguay.
Cancer Res 1990;50:426–31.
12. Graham S, Marshall J, Haughev B, et al. Nutritional epi-
demiology of cancer of the esophagus. Am J Epidemiol
1990;131:454–67.
13. Franceschi S, Talamini R, Barra S, et al. Smoking and drink-
ing in relation to cancers of the oral cavity, pharynx, larynx,
and esophagus in northern Italy. Cancer Res 1990;50:
6502–7.
14. Sankaranarayanan R, Duffy SW, Padmakumary G, et al.
Risk factors for cancer of the oesophagus in Kerala, India.
Znt J Cancer 1991;49:485–9.
15. Cheng KK, Day NE, Duffy SW, et al. Pickled vegetables in
the aetiology of oesophageal cancer in Hong Kong Chinese.
Lancet 1992;339:1314–8.
16. Gao YT, McLaughlin JK, Blot WJ, et al. Risk factors for
esophageal cancer in Shanghai, China. I. Role of cigarette
smoking and alcohol drinking. Int J Cancer 1994;58:192–6.
17. Castelletto R, Castellsague X, Muñoz N, et al. Alcohol, to-
bacco, diet, mate drinking, and esophageal cancer in
Argentina. Cancer Epidemiol Biomarkers Prev 1994;3:
557–64.
18. Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol, and
tobacco as risk factors for cancers of the esophagus and
gastric cardia: adenocarcinoma versus squamous cell car-
cinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85–92.
19. Castellsague X, Munoz N, De Stefani E, et al. Independent
and joint effects of tobacco smoking and alcohol drinking
on the risk of esophageal cancer in men and women. Int J
Cancer 1999;82:657–64.
20. Lagergren J, Bergstrom R, Lindgren A, et al. The role of 
tobacco, snuff and alcohol use in the aetiology of cancer
of the oesophagus and gastric cardia. Int J Cancer 2000;
85:340–6.
21. Wu MT, Lee YC, Chen CJ, et al. Risk of betel chewing 
for oesophageal cancer in Taiwan. Br J Cancer 2001;85:
658–60.
22. Gallus S, Altieri A, Bosetti C, et al. Cigarette tar yield and
risk of upper digestive tract cancers: case-control studies
from Italy and Switzerland. Ann Oncol 2003;14:209–13.
23. Lee CH, Lee JM, Wu DC, et al. Independent and com-
bined effects of alcohol intake, tobacco smoking and betel
quid chewing on the risk of esophageal cancer in Taiwan.
Int J Cancer 2005;113:475–82.
24. Garavello W, Negri E, Talamini R, et al. Family history of
cancer, its combination with smoking and drinking, and
risk of squamous cell carcinoma of the esophagus. Cancer
Epidemiol Biomarkers Prev 2005;14:1390–3.
Secondary prevention for esophageal cancer
J Formos Med Assoc | 2010 • Vol 109 • No 6 419
25. Wu IC, Lu CY, Kuo FC, et al. Interaction between cigarette,
alcohol and betel nut use on esophageal cancer risk in
Taiwan. Eur J Clin Invest 2006;36:236–41.
26. Hashibe M, Boffetta P, Janout V, et al. Esophageal cancer
in Central and Eastern Europe: tobacco and alcohol. Int J
Cancer 2007;120:1518–22.
27. Wang JM, Xu B, Rao JY, et al. Diet habits, alcohol drinking,
tobacco smoking, green tea drinking, and the risk of
esophageal squamous cell carcinoma in the Chinese pop-
ulation. Eur J Gastroenterol Hepatol 2007;19:171–6.
28. Nasrollahzadeh D, Kamangar F, Aghcheli K, et al. Opium,
tobacco, and alcohol use in relation to oesophageal squa-
mous cell carcinoma in a high-risk area of Iran. Br J Cancer
2008;98:1857–63.
29. Pandeya N, Williams G, Green AC, et al. Australian Cancer
Study. Alcohol consumption and the risks of adenocarci-
noma and squamous cell carcinoma of the esophagus.
Gastroenterology 2009;136:1215–24,e1–2.
30. Yen AM, Chen SC, Chen TH. Dose-response relationships
of oral habits associated with the risk of oral pre-malignant
lesions among men who chew betel quid. Oral Oncol
2007;43:634–8.
31. Yen AM, Chen LS, Chiu YH, et al. A prospective community-
population-registry-based cohort study of the association
between betel-quid chewing and cardiovascular disease
in men in Taiwan. Am J Clin Nutr 2008;87:70–8.
32. Yen AM, Chiu YH, Chen LS, et al. A population-based
study of the association between betel-quid chewing and
the metabolic syndrome in men. Am J Clin Nutr 2006;83:
1153–60.
33. Wu GH, Boucher BJ, Chiu YH, et al. Impact of chewing
betel-nut (Areca catechu) on liver cirrhosis and hepatocel-
lular carcinoma: a population-based study from an area with
a high prevalence of hepatitis B and C infections. Public
Health Nutr 2009;12:129–35.
34. Chen TH, Chiu YH, Boucher BJ. Transgenerational effects
of betel-quid chewing on the development of the meta-
bolic syndrome in the Keelung Community-based Integrated
Screening Program. Am J Clin Nutr 2006;83:688–92.
35. Goan YG, Chang HC, Hsu HK, et al. Risk of p53 gene muta-
tion in esophageal squamous cell carcinoma and habit of
betel quid chewing in Taiwanese. Cancer Sci 2005;96:
758–65.
36. Li Y, Ma J, Guo Q, et al. Overexpression of MMP-2 and
MMP-9 in esophageal squamous cell carcinoma. Dis
Esophagus 2009;22:664–7.
37. Langevin SM, Lin D, Matsuo K, et al. Review and pooled
analysis of studies on MTHFR C677T polymorphism and
esophageal cancer. Toxicol Lett 2009;184:73–80.
38. Upadhyay R, Jain M, Kumar S, et al. Association of inter-
leukin-6 (-174G > C) promoter polymorphism with risk of
squamous cell esophageal cancer and tumor location: an
exploratory study. Clin Immunol 2008;128:199–204.
39. Lee CH, Lee JM, Wu DC, et al. Carcinogenetic impact of
ADH1B and ALDH2 genes on squamous cell carcinoma 
risk of the esophagus with regard to the consumption of
alcohol, tobacco and betel quid. Int J Cancer 2008;122:
1347–56.
40. Yokoyama A, Omori T. Genetic polymorphisms of alcohol
and aldehyde dehydrogenases and risk for esophageal
and head and neck cancers. Alcohol 2005;35:175–85.
41. Hashibe M, Mckay JD, Curado MP, et al. Multiple ADH
genes are associated with upper aerodigestive cancers.
Nat Genet 2008;40:707–9.
42. Chuang SC, Scelo G, Tonita JM, et al. Risk of second pri-
mary cancer among patients with head and neck cancers:
A pooled analysis of 13 cancer registries. Int J Cancer
2008;123:2390–6.
43. Wang CP, Lee YC, Yang TL, et al. Application of unsedated
transnasal esophagogastroduodenoscopy in the diagnosis
of hypopharyngeal cancer. Head Neck 2009;31:153–7.
44. Wang CP, Lee YC, Lou PJ. Unsedated transnasal esopha-
gogastroduodenoscopy for the evaluation of dysphagia
following treatment for previous primary head and neck
cancer. Oral Oncol 2009;45:615–20.
45. Yokoyama A, Yokoyama T, Muramatsu T, et al. Macrocyto-
sis, a new predictor for esophageal squamous cell carcinoma
in Japanese alcoholic men. Carcinogenesis 2003;24:1773–8.
46. Chang HW, Ling GS, Wei WI, et al. Smoking and drinking
can induce p15 methylation in the upper aerodigestive
tract of healthy individuals and patients with head and
neck squamous cell carcinoma. Cancer 2004;101:125–32.
47. Abbaszadegan MR, Raziee HR, Ghafarzadegan K, et al.
Aberrant p16 methylation, a possible epigenetic risk fac-
tor in familial esophageal squamous cell carcinoma. Int J
Gastrointest Cancer 2005;36:47–54.
48. Wei WQ, Abnet CC, Lu N, et al. Risk factors for oesophageal
squamous dysplasia in adult inhabitants of a high risk region
of China. Gut 2005;54:759–63.
49. Fagundes RB, Melo CR, Pütten ACK, et al. p53 immuno-
expression: An aid to conventional methods in the screen-
ing of precursor lesions of squamous esophageal cancer in
patients at high-risk? Cancer Detect Prev 2005;29:227–32.
50. Fang MZ, Jin Z, Wang Y, et al. Promoter hypermethylation
and inactivation of O(6)- methylguanine-DNA methyl-
transferase in esophageal squamous cell carcinomas and
its reactivation in cell lines. Int J Oncol 2005;26:615–22.
51. Roth MJ, Abnet CC, Hu N, et al. p16, MGMT, RARbeta2,
CLDN3, CRBP and MT1G gene methylation in esophageal
squamous cell carcinoma and its precursor lesions. Oncol
Rep 2006;15:1591–7.
52. Anupam K, Tusharkant C, Gupta SD, et al. Loss of disabled-
2 expression is an early event in esophageal squamous tu-
morigenesis. World J Gastroenterol 2006;12:6041–5.
53. Guo M, Ren J, House MG, et al. Accumulation of pro-
moter methylation suggests epigenetic progression in
squamous cell carcinoma of the esophagus. Clin Cancer
Res 2006;12:4515–22.
54. Kaneko K, Katagiri1 A, Konishi K, et al. Study of p53 gene
alteration as a biomarker to evaluate the malignant risk of 
C.S. Chung, et al
420 J Formos Med Assoc | 2010 • Vol 109 • No 6
Lugol-unstained lesion with non-dysplasia in the oesopha-
gus. Br J Cancer 2007;96:492–8.
55. Ishii T, Murakami J, Notohara K, et al. Oesophageal squa-
mous cell carcinoma may develop within a background of
accumulating DNA methylation in normal and dysplastic
mucosa. Gut 2007;56:13–9.
56. Zhou YZ, Fang XQ, Li H, et al. Role of serum angiopoietin-
2 level in screening for esophageal squamous cell cancer
and its precursors. Chin Med J 2007;120:1216–9.
57. He S, Guo GM, Liu FX, et al. Molecular analysis in combi-
nation with iodine staining may contribute to the risk pre-
diction of esophageal squamous cell carcinoma. J Cancer
Res Clin Oncol 2008;134:307–15.
58. Yokoyama T, Yokoyama A, Kumagai Y, et al. Health risk
appraisal models for mass screening of esophageal cancer
in Japanese men. Cancer Epidemiol Biomarkers Prev
2008;17:2846–54.
59. Adams L, Roth MJ, Abnet CC, et al. Promoter methylation
in cytology specimens as an early detection marker for
esophageal squamous dysplasia and early esophageal squa-
mous cell carcinoma. Cancer Prev Res 2008;1:357–61.
60. Kamangar F, Diaw L, Wei WQ, et al. Serum pepsinogens
and risk of esophageal squamous dysplasia. Int J Cancer
2009;124:456–60.
61. Yokoyama A, Kumagai Y, Yokoyama T, et al. Health risk
appraisal models for mass screening for esophageal and
pharyngeal cancer: an endoscopic follow-up study of 
cancer-free Japanese men. Cancer Epidemiol Biomarkers
Prev 2009;18:651–5.
62. Varadarajulu S, Eloubeidi MA, Patel RS, et al. The yield
and the predictors of esophageal pathology when upper
endoscopy is used for the initial evaluation of dysphagia.
Gastrointest Endosc 2005;61:809–11.
63. Yokoyama T, Yokoyama A, Kato H, et al. Alcohol flushing,
alcohol and aldehyde dehydrogenase genotypes, and risk
for esophageal squamous cell carcinoma in Japanese men.
Cancer Epidemiol Biomarkers Prev 2003;12:1227–33.
64. Iijima K, Koike T, Abe Y, et al. Extensive gastric atrophy: 
an increased risk factor for superficial esophageal squa-
mous cell carcinoma in Japan. Am J Gastroenterol 2007;
102:1603–9.
65. Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens
and risk of gastric and esophageal cancers in the General
Population Nutrition Intervention Trial cohort. Gut 2009;
58:636–42.
66. Cheung WY, Liu G. Genetic variations in esophageal cancer
risk and prognosis. Gastroenterol Clin North Am 2009;38:
75–91.
67. Hibi K, Taguchi M, Nakayama H, et al. Molecular detec-
tion of p16 promoter methylation in the serum of patients
with esophageal squamous cell carcinoma. Clin Cancer
Res 2001;7:3135–8.
68. Oka D, Yamashita S, Tomioka T, et al. The presence of
aberrant DNA methylation in noncancerous esophageal
mucosae in association with smoking history: a target for 
risk diagnosis and prevention of esophageal cancers.
Cancer 2009;115:3412–26.
69. Shiozaki H, Tahara H, Kobayashi K, et al. Endoscopic
screening of early esophageal cancer with the Lugol dye
method in patients with head and neck cancers. Cancer
1990;66:2068–71.
70. Okumura T, Aruga H, Inohara H, et al. Endoscopic exami-
nation of the upper gastrointestinal tract for the presence
of second primary cancers in head and neck cancer pa-
tients. Acta Otolaryngol (Stockh) 1993;501:103–6.
71. Yokoyama A, Ohmori T, Makuuchi H, et al. Successful
screening for early esophageal cancer in alcoholics using
endoscopy and mucosa iodine staining. Cancer 1995;15:
928–34.
72. Meyer V, Burtin P, Bour B, et al. Endoscopic detection of
early esophageal cancer in a high-risk population: does
Lugol staining improved videoendoscopy? Gastrointest
Endosc 1997;45:480–4.
73. Dawsey SM, Fleischer DE, Wang GQ, et al. Mucosal io-
dine staining improves endoscopic visualization of squa-
mous dysplasia and squamous cell carcinoma of the
esophagus in Linxian, China. Cancer 1998;83:220–31.
74. Freitag CPF, Barros SGS, Krudel CDP, et al. Esophageal
dysplasias are detected by endoscopy with Lugol in pa-
tients at risk for squamous cell carcinoma in Southern
Brazil. Dis Esophagus 1999;12:191–5.
75. Tincani AJ, Brandalise N, Altemani A, et al. Diagnosis of
superficial esophageal cancer and dysplasia using endo-
scopic screening with a 2% Lugol dye solution in patients
with head and neck cancer. Head Neck 2000;22:170–4.
76. Mayinger B, Horner P, Jordan M, et al. Light-induced auto-
fluorescence spectroscopy for the endoscopic detection of
esophageal cancer. Gastrointest Endosc 2001;54:195–201.
77. Muto M, Hironaka S, Nakane M, et al. Association of 
multiple Lugol-voiding lesions with synchronous and
metachronous esophageal squamous cell carcinoma in
patients with head and neck cancer. Gastrointest Endosc
2002;56:517–21.
78. Yoshida T, Inoue H, Usui S, et al. Narrow-band imaging
system with magnifying endoscopy for superficial esoph-
ageal lesions. Gastrointest Endosc 2004;59:288–95.
79. Uedo N, Iishi H, Tatsuta M, et al. A novel videoendoscopy
system by using autofluorescence and reflectance imaging
for diagnosis of esophagogastric cancers. Gastrointest
Endosc 2005;62:521–8.
80. Hashimoto CL, Iriya K, Baba ER, et al. Lugol’s dye spray
chromoendoscopy establishes early diagnosis of esoph-
ageal cancer in patients with primary head and neck cancer.
Am J Gastroenterol 2005;100:275–82.
81. Dubuc J, Legoux JL, Winnock M, et al. Endoscopic screen-
ing for esophageal squamous cell carcinoma in high-risk
patients: a prospective study conducted in 62 French en-
doscopy centers. Endoscopy 2006;38:690–5.
82. Möschler O, Spahn TW, Bisping CM, et al. Chromo-
endoscopy is a valuable tool for screening of high-risk 
Secondary prevention for esophageal cancer
J Formos Med Assoc | 2010 • Vol 109 • No 6 421
patients with head and neck cancer for early detection of
esophageal cancer. Digestion 2006;73:160–6.
83. Lee YC, Wang CP, Chen CC, et al. Transnasal endoscopy
with narrow-band imaging and Lugol staining to screen
patients with head and neck cancer whose condition lim-
its oral intubation with standard endoscope. Gastrointest
Endosc 2009;69:408–17.
84. Yoshida Y, Goda K, Tajiri H, et al. Assessment of novel en-
doscopic techniques for visualizing superficial esophageal
squamous cell carcinoma: autofluorescence and narrow-
band imaging. Dis Esophagus 2009;22:439–46.
85. Lee CT, Chang CY, Tai CM, et al. Endoscopic screening of
esophageal cancer in patients with head and neck cancers:
a prospective study by comparison of narrow-band-imaging
with high-magnification and conventional endoscopy.
Gastrointest Endosc 2009;69:AB347.
86. Takubo K, Aida J, Sawabe M, et al. Early squamous cell
carcinoma of the oesophagus: the Japanese viewpoint.
Histopathology 2007;51:733–42.
87. Katada C, Muto M, Manabe T, et al. Local recurrence of
squamous-cell carcinoma of the esophagus after EMR.
Gastrointest Endosc 2005;61:219–25.
88. Muto M, Katada C, Sano Y, et al. Narrow band imaging: 
a new diagnostic approach to visualize angiogenesis in 
superficial neoplasia. Clin Gastroenterol Hepatol 2005;3:
S16–20.
89. Curvers WL, Singh R, Song LM, et al. Endoscopic tri-
modal imaging for detection of early neoplasia in Barrett’s
oesophagus: a multi-centre feasibility study using high-
resolution endoscopy, autofluorescence imaging and nar-
row band imaging incorporated in one endoscopy system.
Gut 2008;57:167–72.
90. Somerville M, Garside R, Pitt M, et al. Surveillance of
Barrett’s oesophagus: is it worthwhile? Eur J Cancer 2008;
44:588–99.
91. Barbiere JM, Lyratzopoulos G. Cost-effectiveness of endo-
scopic screening followed by surveillance for Barrett’s
esophagus: a review. Gastroenterology 2009;137:1869–76.
